Hypertension, arterial thromboembolism, pulmonary hypertension, cardiac ischemia, and QT prolongation are the main adverse effects associated with VEGF-inhibiting agents.138,139 Cardiomyopathy is a relatively infrequent adverse event of VEGF inhibitors in the absence of additional insults and may predominantly occur when other cardiovascular adverse event ensue (i.e. severe hypertension). Here, VEGFA is linked to pulmonary hypertension.